The two will partner on a phase I clinical trial that will study the use of a T cell receptor-based candidate to treat cancers that express the Kita-Kyushu lung cancer antigen 1 (KK-LC-1) -- such as gastric, cervical, lung, and triple-negative breast cancers, T-Cure Biosciences said.

The company acquired the KK-LC-1 therapy under an exclusive global license with the U.S. National Cancer Institute (NCI) in 2020. T-Cure isolates high-avidity T-cell receptors that can be used to engineer a patient's T cells to effectively target and destroy solid tumors, it said.

The trial will be led by Dr. Christian Hinrichs, chief of the cancer immunotherapy section and co-director of the Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey, according to T-Cure. It will begin in the second quarter of this year at the NCI but will be transferred back to Rutgers in the second half of 2021.

Financial details of the collaboration were not disclosed.

Immunotech to develop T-Cure's TCR therapy in China
T-Cure Bioscience has entered into a license agreement with Immunotech Biopharm for the research and development of T-Cure's 800TCR candidate, a human...